Featured Research

from universities, journals, and other organizations

Targeted therapy prolongs life in patients with HER2-positive breast cancer

Date:
December 27, 2009
Source:
Duke University Medical Center
Summary:
Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to new research.

Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center. Blackwell presented the findings onDecember 11 at the CTRC-AACR San Antonio Breast Cancer Symposium.

Related Articles


Blackwell says the combination targeted therapy gave patients more than a four-month survival advantage over those who took lapatinib alone. She says the findings may be the first step toward a chemotherapy-free future.

"This is the first time that a pair of targeted therapies has been shown to be superior to any intervention that paired a targeted therapy with a hormonal or chemotherapy based approach," she said.

The results stem from a large, Phase III clinical trial where investigators randomized 296 patients with metastatic breast cancer to receive either lapatinib (also known as Tykerb) alone or lapatinib plus trastuzumab (Herceptin) once a day. All participants had metastatic disease that had continued to spread even after treatments with several interventions that included trastuzumab plus chemotherapy.

Blackwell says trastuzumab binds to and blocks part of the HER2 growth factor that appears on the surface of some breast cancer cells while lapatinib binds to a second growth factor, EGFR, and part of HER2 that sits below the cell surface. "It's sort of a double whammy, disabling the HER2 protein in two places instead of one."

Women who enrolled in the single-agent arm of the study and whose cancer continued to spread after four weeks were allowed to cross over to the other arm of the study to continue on the combined approach.

Fifty-two percent of the women enrolled in the lapatinib-only arm of the study crossed over to the combination arm. The median overall survival following treatment with lapatinib plus trastuzumab was 60.7 weeks compared to 41.4 weeks for those who took only lapatinib.

Other researchers involved in the study include Hal Burstein, from the Dana Farber Cancer Institute; George Sledge, from Indiana University Cancer Center; Steven Stein, Catherine Ellis, and Michelle Casey, of GlaxoSmithKline; Jose Baselga, of Vall d'Hebron University Hospital, Barcelona, Spain; and Joyce O'Shaughnessy from Baylor Sammons Cancer Center, Texas Oncology, PA, US Oncology, Dallas.


Story Source:

The above story is based on materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Duke University Medical Center. "Targeted therapy prolongs life in patients with HER2-positive breast cancer." ScienceDaily. ScienceDaily, 27 December 2009. <www.sciencedaily.com/releases/2009/12/091211150324.htm>.
Duke University Medical Center. (2009, December 27). Targeted therapy prolongs life in patients with HER2-positive breast cancer. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2009/12/091211150324.htm
Duke University Medical Center. "Targeted therapy prolongs life in patients with HER2-positive breast cancer." ScienceDaily. www.sciencedaily.com/releases/2009/12/091211150324.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins